Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression

Liu,Zhining; Dai,Hongliang; Jia,Guizhi; Li,Yuhong; Liu,Xin; Ren,Weidong

doi:10.3892/ol.2015.2966

Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression

Authors:
- Zhining Liu
- Hongliang Dai
- Guizhi Jia
- Yuhong Li
- Xin Liu
- Weidong Ren
View Affiliations

Affiliations: Ultrasound Department, Shengjing Hospital, China Medical University, Shenyang, Liaoning 110004, P.R. China, School of Nursing, Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Biochemistry and Molecular Biology, Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Ultrasound Department, First Affiliated Hospital, Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Clinical Laboratory, First Affiliated Hospital, Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: February 16, 2015 https://doi.org/10.3892/ol.2015.2966
Pages: 1893-1896

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aims of the current study were to investigate the influence of insufficient radiofrequency ablation (RFA) on the cell proliferation of the human hepatocellular carcinoma (HCC) cells, SMMC7721, and to elucidate the underlying mechanism. SMMC7721 cells were subjected to a 47˚C treatment regimen to simulate insufficient RFA, in the presence or absence of KN93 [a specific inhibitor of Ca2+/calmodulin‑dependent protein kinase II (CaMKII)], PD98059 [a specific inhibitor of extracellular signal‑regulated kinase (ERK)], or axitinib (a specific inhibitor of vascular endothelial growth factor (VEGF) receptor]. Cell proliferation was determined using a thiazolyl terazolium assay (MTT). The levels of CaMKII, phospho‑CaMKII, ERK, phospho‑ERK and VEGF were observed by western blot analysis. The results demonstrated that the 47˚C treatment regimen: i) Triggered upregulation of VEGF expression in the SMMC7721 cells, which was reduced by CaMKII or ERK inhibition; ii) induced ERK activation was prevented by KN93; and iii) promoted SMMC7721 cell proliferation, which was greatly inhibited by axitinib, KN93 and PD98059. In conclusion, the results indicated that insufficient RFA promotes SMMC7721 cell proliferation by activating CaMKII/ERK‑dependent VEGF overexpression.

View Figures

View References

1	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 15(Suppl 4): 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
3	Lau WY, Lai EC and Lau SH: The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 8:124–133. 2009.PubMed/NCBI
4	Menon KV, Hakeem AR and Heaton ND: Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther. 40:893–902. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A and Cherqui D: Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am. 17:607–633. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lencioni R: Loco-regional treatment of hepatocellular carcinoma. Hepatology. 52:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
7	Lau WY and Lai EC: The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 249:20–25. 2009. View Article : Google Scholar
8	Obara K, Matsumoto N, Okamoto M, et al: Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2:116–123. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kong J, Kong J, Pan B, et al: Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA. PloS One. 7:e372662012. View Article : Google Scholar
10	Zhao K, Song X, Huang Y, et al: Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-κB signaling. Eur J Pharmacol. 737:57–69. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kaseb AO, Morris JS, Hassan MM, et al: Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 29:3892–3899. 2011. View Article : Google Scholar : PubMed/NCBI
13	Dong S, Kong J, Kong F, et al: Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med. 11:2732013. View Article : Google Scholar : PubMed/NCBI
14	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
15	Yamada S, Utsunomiya T, Morine Y, et al: Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol. 21(Suppl 3): S436–S442. 2014. View Article : Google Scholar : PubMed/NCBI
16	Santoni M, Berardi R, Amantini C, et al: Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer. 134:2772–2777. 2014. View Article : Google Scholar
17	Xue L, Li M, Chen T, et al: PE-induced apoptosis in SMMC-7721 cells: Involvement of Erk and Stat signalling pathways. Int J Mol Med. 34:119–129. 2014.PubMed/NCBI
18	Maier LS: Role of CaMKII for signaling and regulation in the heart. Front Biosci (Landmark Ed). 14:486–496. 2009. View Article : Google Scholar
19	Russo E, Salzano M, De Falco V, et al: Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor alpha in medullary thyroid cancer. Clin Cancer Res. 20:1513–1520. 2014. View Article : Google Scholar : PubMed/NCBI
20	Rusciano MR, Salzano M, Monaco S, et al: The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC. Endocr Relat Cancer. 17:113–123. 2010. View Article : Google Scholar